In that vein, Viking Therapeutics (NASDAQ: VKTX) and Zealand Pharma (OTC: ZLDP.F) are among the best biotechs aiming to enter ...

Our first obesity drugs will come to the market significantly faster than people are expecting, potentially by 2028, says ...

Roche believes its anti-obesity drugs could have advantages over other more established rivals such as Eli Lilly and Novo ...

Research shows the drug can cut the risk of serious cardiovascular issues like heart attack and stroke in certain patients.

GLP-1 medicines, mostly acylated peptides like semaglutide and liraglutide, have pleiotropic effects beyond weight and ...

It makes sense why Pfizer wants to compete in the market for weight loss therapies. There's more than one credible estimate ...

Eli Lilly shares dropped more than 4% on Thursday as investors assessed the possible impact of a promising new weight-loss ...

Healthcare company Roche said its trial-stage daily pill showed an average 6.1 percent weight loss in four weeks ...

The authors advocate for a consideration of 2 distinct phases of obesity management (ie, active weight loss and maintenance of weight loss) to allow substantially more people access to antiobesity ...

Opinion: Our guest opinion writers argue that more can be done to help troops get their physical fitness squared away, both ...

The program aims to help people lose weight and keep it off, even after they stop weight-loss meds, in order to prevent ...

Swiss drugmaker Roche plans to accelerate the development of its anti-obesity drugs to challenge rivals like Eli Lilly and ...